Retinopathy of Prematurity (ROP) Clinical Trial
Official title:
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
This is a Phase 3, randomized, double-masked, placebo-controlled study designed to determine the effectiveness of myo-Inositol 5% Injection to increase the incidence of survival without severe Retinopathy of Prematurity (ROP) through acute/final ROP determination up to 55 weeks postmenstrual age (PMA) in premature infants <28 0/7 weeks' gestation.
Approximately 1760 infants are to be enrolled at approximately 18 Eunice Kennedy Shriver
National Institute of Child Health and Human Development (NICHD) Neonatal Research Network
(NRN) Centers (approximately 44 sites) in the United States. Infants meeting the study
selection criteria and for whom informed consent is obtained will be randomized to receive
either 80 mg inositol/kg/day or placebo, administered in divided doses every 12 hours (40
mg/kg/dose). Study drug will be administered daily, starting within 12 to 72 hours of birth
and continued until the earliest of 34 weeks PMA, 10 weeks chronologic age, or the time of
hospital discharge or transfer. Inositol or placebo will be administered IV until enteral
feedings reach 120ml/kg/day (or sooner if the infant is no longer receiving IV fluids), at
which time the same dose and formulation will be administered enterally every 12 hours.
For publication purposes, the analysis of the primary efficacy outcome will consider the
entire study population. In support of a new drug application (NDA) for use of myo-Inositol
5% Injection to increase survival without severe ROP through the determination of acute/final
ROP status, the analysis of the primary efficacy outcome will be conducted for the entire
study population and separately within pre-specified regulatory sub-studies created by
administratively splitting infants enrolled at each study center into two sub-studies.
Assessments performed during the study include customary newborn intensive care procedures
including repeat eye examinations until ROP status is final (which often extends after
discharge), measurements of growth, cranial ultrasounds or other imaging per usual practice,
and the collection of clinical diagnoses throughout hospitalization to evaluate other common
morbidities of extreme preterm birth. Adverse events will be recorded from time of treatment
initiation until 7 days after the last dose of study drug, and concurrent medications will be
recorded from 24 hours prior to randomization until 7 days after the last dose of study drug
or until discharge or transfer if sooner. Using the separate NICHD Follow-up protocol, longer
term data will be collected at 22-26 months corrected age, including growth,
neurodevelopmental testing, overall health status, rehospitalizations, surgeries and
diagnoses, including ophthalmic diagnoses and treatments since discharge.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04506619 -
Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
|
||
Completed |
NCT04004208 -
Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy
|
Phase 3 | |
Recruiting |
NCT03253263 -
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
|
Phase 2 | |
Completed |
NCT02386839 -
Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)
|
Phase 2 | |
Withdrawn |
NCT01470430 -
VEGF In Systemic Circulation Of ROP-infants
|
N/A | |
Completed |
NCT01054027 -
Study on Effective Mydriasis in Premature Infants
|
N/A | |
Active, not recruiting |
NCT04015180 -
Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090
|
Phase 3 | |
Completed |
NCT01096784 -
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
|
Phase 2 | |
Completed |
NCT02640664 -
Rainbow Extension Study
|
Phase 3 | |
Completed |
NCT02134457 -
Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity
|
Phase 2 |